When was Precision NeuroMed founded?

Precision NeuroMed was founded in 2023.

Where is Precision NeuroMed located?

Precision NeuroMed is headquartered in Woodside, United States.

How many employees does Precision NeuroMed have?

As of Jun 30, 2026, the latest employee count at Precision NeuroMed is 9.

Where does Precision NeuroMed rank among its competitors?

Precision NeuroMed ranks 11th amongst 31 active competitors, of which 11 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Basilea, which secured $13.3M in May, 2026.

Who are the top competitors of Precision NeuroMed?

Precision NeuroMed's top competitors include Imvax, Basilea and SOM Biotech. Among them, Basilea secured the most recent funding round in May, 2026.

Precision NeuroMed - 2026 Company Profile, Team & Competitors

Precision NeuroMed is an unfunded company based in Woodside (United States), founded in 2023 by Krystof Bankiewicz and Purvi Kunwar. It operates as a Provider of CNS therapeutic platform for neurological treatments to improve brain and nerve health. Precision NeuroMed has not raised any funding yet. The company has 31 active competitors, including 11 funded and 5 that have exited. Its top competitors include companies like Imvax, Basilea and SOM Biotech.

Company Details

Provider of CNS therapeutic platform for neurological treatments to improve brain and nerve health. It offers neurosurgery, electrophysiology, and AI technology to design and develop treatments. It offers a pipeline of drug candidates which include IL13-PE38 is a fusion protein that combines interleukin-13 and Pseudomonas exotoxin A for glioblastomas and other cancers.

Website: precisionneuromed.com
Email ID: *****@precisionneuromed.com

Key Metrics

Founded Year

2023

Location

Woodside, United States

Stage

Unfunded

Ranked

11^th among 31 active competitors

Employee Count

9 as on Jun 30, 2026

Similar Companies

Imvax & 37 more

View Precision NeuroMed's full profile

Precision NeuroMed has not raised any funding rounds yet.

The founders of Precision NeuroMed are Krystof Bankiewicz and Purvi Kunwar.

Here are the details of Precision NeuroMed's key team members:

Krystof Bankiewicz: Co-Founder of Precision NeuroMed and founder of 1 other company.
Purvi Kunwar: Co-Founder of Precision NeuroMed.

View details of Precision NeuroMed's Founder profiles and Board Members

Precision NeuroMed's employee count trend

Precision NeuroMed has 9 employees as of Jun 26. Here is Precision NeuroMed's employee count trend over the years:

Employee count trend for Precision NeuroMed

Uncover Precision NeuroMed's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Precision NeuroMed include Imvax, Basilea and SOM Biotech. Here is the list of Top 10 competitors of Precision NeuroMed, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Imvax 2015, Philadelphia (United States), Series C	Personalized immunotherapies targeting solid tumors, stimulating innate and adaptive immunity	$204M	Hp Wild Holding, Invus & 4 others	62/100
2nd	Basilea 1999, Basel (Switzerland), Public	Developer of antibiotics, antifungals, and oncology drugs for treating multiple diseases	-	Athyrium Capital Management, Medical Countermeasures ... & 2 others	59/100
3rd	SOM Biotech 2009, Barcelona (Spain), Series B	Developer of platform for screening compounds to treat rare diseases	$28.5M	European Investment Bank, Prevail Partners ... & 3 others	53/100
4th	Ayala Pharma 2017, Wilmington (United States), Public	Developer of small molecule-based therapeutics for cancer treatment	$50.6M	Novartis, Bristol-Myers Squibb & 9 others	49/100
5th	Argent BioPharma 2023, London (United Kingdom), Public	Drug discovery company focused on the central nervous system and immunology	-	-	47/100
6th	AimedBio 2018, Seoul (South Korea), Public	Developer of screening platform for brain drug discovery and efficacy	-	Samsung Life Science	43/100
7th	Batea Oncology 2024, Santiago de Compostela (Spain), Seed	A biotech company developing therapies for glioblastoma	-	-	35/100
8th	Curtana Pharma 2013, Austin (United States), Seed	Developer of small molecule inhibitors targeting brain cancer stem cells	-	Austin Technology Incubator, EIC Fund & 7 others	34/100
9th	Lin BioScience 2016, San Diego (United States), Public	Biopharmaceutical company discovering innovative drugs for cancer and eye diseases	-	-	33/100
10th	entrinsic bioscience 2012, Norwood (United States), Series A	Developer of drugs for treating tumour, cystic fibrosis, and hemochromatosis	$19.2M	Johnson & Johnson Innovation	33/100
11th	Precision NeuroMed 2023, Woodside (United States), Unfunded	Provider of CNS therapeutic platform for neurological treatments to improve brain and nerve health	-	-	33/100